Non-alcoholic fatty liver disease in type 2 diabetes: Pathogenesis and treatment options

Current Vascular Pharmacology

Volumn 10, Issue 2, 2012, Pages 162-172

  Tziomalos, Konstantinos ^a   Athyros, Vassilios G ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Cardiovascular disease; Insulin resistance; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Oxidative stress; Pathogenesis; Treatment; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; APOLIPOPROTEIN B100; ASCORBIC ACID; ATORVASTATIN; CYTOKERATIN 18; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FERRITIN; GEMFIBROZIL; GLUCOSE; ICOSAPENTAENOIC ACID; INSULIN; LOSARTAN; METFORMIN; NICOTINIC ACID; PENTOXIFYLLINE; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BARIATRIC SURGERY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIFE STYLE; OBESITY; OXIDATIVE STRESS; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 84857132090     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112799305012     Document Type: Article

References (224)

1. Vuppalanchi R, Chalasani N. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
2. Adams LA, Sanderson S, Lindor KD, et al. The histological course of non-alcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-8.
3. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74.
4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
5. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-8.
6. Williams CD, Stengel J, Asike MI, et al. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
7. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
8. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-30.
9. Lee YJ, Shim JY, Moon BS, et al. The relationship between arterial stiffness and non-alcoholic fatty liver disease. Dig Dis Sci 2012; 57: 196-203.
10. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-7.
11. Adams LA, Lymp JF, St SJ, et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
12. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
13. Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking non-alcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 2011; 56: 3439-49.
14. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
15. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
16. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
17. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137: 865-72.
18. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
19. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with non-alcoholic fatty liver disease. Hepatology 2010; 52: 913-24.
20. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with non-alcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
21. Younossi ZM, Gramlich T, Matteoni CA, et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262-5.
22. Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-9.
23. Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-8.
24. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
25. Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
26. Forbes S, Taylor-Robinson SD, Patel N, et al. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia 2011; 54: 641-7.
27. Cerda C, Perez-Ayuso RM, Riquelme A, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 412-7.
28. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, et al. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501.
29. Daskalopoulos GN, Karkanaki A, Karagiannis A, et al. Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome? Angiology 2011; 62: 285-90.
30. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49: 755-65.
31. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Role of ethnicity in overweight and obese patients with non-alcoholic steatohepatitis. Hepatology 2011; 54: 837-45.
32. Tabibian JH, Lazo M, Durazo FA, et al. Non-alcoholic fatty liver vdisease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol 2011; 26: 501-9.
33. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-50.
34. Hwang ST, Cho YK, Yun JW, et al. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010; 40: 437-42.
35. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with non-alcoholic fatty liver disease. J Am Soc Nephrol 2008; 19: 1564-70.
36. Arase Y, Suzuki F, Kobayashi M, et al. The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011; 50: 1081-7.
37. Targher G, Bertolini L, Padovani R, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest 2006; 29: 55-60.
38. Targher G, Bertolini L, Poli F, et al. Non-alcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-6.
39. Adams LA, Harmsen S, St Sauver JL, et al. Non-alcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-73.
40. Jaskiewicz K, Rzepko R, Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci 2008; 53: 785-8.
41. Tordjman J, Poitou C, Hugol D, et al. Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status. J Hepatol 2009; 51: 354-62.
42. Bacon BR, Farahvash MJ, Janney CG, et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
43. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
44. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in non-alcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.
45. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
46. Leite NC, Villela-Nogueira CA, Pannain VL, et al. Histopathological stages of non-alcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31: 700-6.
47. Smith BW, Adams LA. Non-alcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011; 7: 456-65.
48. Adams LA, Waters OR, Knuiman MW, et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861-7.
49. Bae JC, Rhee EJ, Lee WY, et al. Combined effect of non-alcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34: 727-9.
50. Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32: 741-50.
51. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52: 1056-60.
52. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-5.
53. Gastaldelli A, Cusi K, Pettiti M, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in non-diabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496-506.
54. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-5.
55. Bhathena J, Kulamarva A, Martoni C, et al. Diet-induced metabolic hamster model of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes 2011; 4: 195-203.
56. Charlton M, Krishnan A, Viker K, et al. The fast food diet mouse - a novel small animal model of nash with high histologic and physiologic fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011; 301: G825-34.
57. Ogasawara M, Hirose A, Ono M, et al. A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet. Liver Int 2011; 31: 542-51.
58. Anstee QM. Animal models in non-alcoholic steatohepatitis research: utility and clinical translation. Liver Int 2011; 31: 440-2.
59. Angelico F, Del BM, Conti R, et al. Insulin resistance, the metabolic syndrome, and non-alcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-82.
60. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.
61. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-42.
62. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
63. Marchesini G, Brizi M, Bianchi G, et al. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
64. Holt HB, Wild SH, Wood PJ, et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006; 49: 141-8.
65. Kelley DE, McKolanis TM, Hegazi RA, et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906-16.
66. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non-esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 2003; 29: 478-85.
67. Westerbacka J, Kotronen A, Fielding BA, et al. Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with non-alcoholic fatty liver disease. Gastroenterology 2010; 139: 1961-71.
68. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in non-alcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
69. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
70. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatology 2004; 39: 179-87.
71. Svegliati-Baroni G, Ridolfi F, Di SA, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-51.
72. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in non-alcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
73. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
74. Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and non-alcoholic fatty liver disease in people with type 2 diabetes: the edinburgh type 2 diabetes study. Diabetes Care 2011; 34: 1139-44.
75. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113: 1582-8.
76. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-57.
77. Fassio E, Alvarez E, Dominguez N, et al. Natural history of non-alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-6.
78. Musso G, Gambino R, De MF, et al. Nitrosative stress predicts the presence and severity of non-alcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 2007; 86: 661-71.
79. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
80. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002; 37: 56-62.
81. Musso G, Gambino R, Bo S, et al. Should non-alcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in non-obese non-diabetic subjects. Diabetes Care 2008; 31: 562-8.
82. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-502.
83. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
84. Narasimhan S, Gokulakrishnan K, Sampathkumar R, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2010; 43: 815-21.
85. Aubert J, Begriche K, Knockaert L, et al. Increased expression of cytochrome P450 2E1 in non-alcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011; 35: 630-7.
86. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with non-alcoholic fatty liver disease. Hepatology 2003; 38: 428-35.
87. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in non-alcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-74.
88. Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol 2006; 45: 879-81.
89. Ndumele CE, Nasir K, Conceicao RD, et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 1927-32.
90. Athyros VG, Kakafika AI, Karagiannis A, et al. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
91. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
92. Perez-Carreras M, Del HP, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with non-alcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
93. Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in non-alcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.
94. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007; 56: 1960-8.
95. Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-61.
96. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in non-alcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504.
97. Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64: 679-83.
98. Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-26.
99. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
100. Athyros VG, Tziomalos K, Karagiannis A, et al. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-35.
101. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-6.
102. Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2006; 18: 175-80.
103. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.
104. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human non-alcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-64.
105. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human non-alcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
106. Ferreira DM, Castro RE, Machado MV, et al. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia 2011; 54: 1788-98.
107. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of non-alcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-17.
108. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
109. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-9.
110. Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011; 31: 730-9.
111. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
112. Aigner E, Theurl I, Theurl M, et al. Pathways underlying iron accumulation in human non-alcoholic fatty liver disease. Am J Clin Nutr 2008; 87: 1374-83.
113. Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterology 2010; 138: 905-12.
114. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8.
115. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9.
116. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to non-alcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
117. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of non-alcoholic fatty liver disease. Hepatology 2011; 53: 1883-94.
118. Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of non-alcoholic fatty liver disease. Gastroenterology 2010; 139: 1567-76.
119. Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care 2010; 13: 709-14.
120. Okita M, Hayashi M, Sasagawa T, et al. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001; 17: 542-7.
121. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in non-alcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-9.
122. Thomas EL, Brynes AE, Hamilton G, et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-9.
123. Petersen KF, Dufour S, Befroy D, et al. Reversal of non-alcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-8.
124. Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on non-alcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52: 589-93.
125. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072-81.
126. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-83.
127. Sreenivasa BC, Alexander G, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2006; 21: 191-8.
128. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
129. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009; 58: 1281-8.
130. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33: 2156-63.
131. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
132. Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007; 42: 139-47.
133. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
134. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
135. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Acta Diabetol 2009; 46: 113-8.
136. Sofer E, Boaz M, Matas Z, et al. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011; 60: 1278-84.
137. Haukeland JW, Konopski Z, Eggesbo HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-60.
138. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-82.
139. Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy vs. standard therapy alone in non-diabetic patients with insulin resistance and non-alcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009; 2: 157-63.
140. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.
141. Rakoski MO, Singal AG, Rogers MA, et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32: 1211-21.
142. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in non-diabetic subjects with non-alcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-84.
143. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
144. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with non-alcoholic steatohepatitis. Hepatology 2007; 46: 424-9.
145. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
146. Wang CH, Leung CH, Liu SC, et al. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with non-alcoholic fatty liver disease. J Formos Med Assoc 2006; 105: 743-52.
147. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
148. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for non-alcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.
149. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in non-alcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-53.
150. Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007; 56: 1418-24.
151. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-76.
152. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009; 119: 2069-77.
153. Akyuz F, Demir K, Ozdil S, et al. The effects of rosiglitazone, metformin, and diet with exercise in non-alcoholic fatty liver disease. Dig Dis Sci 2007; 52: 2359-67.
154. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18-23.
155. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-13.
156. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
157. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-201.
158. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf. (Accessed August 15, 2011).
159. http://www.afssaps.fr/var/afssaps_site/storage/original/application/4e293bcd0814c025b94d46d7502a0958.pdf. (Accessed August 15, 2011).
160. Juurinen L, Tiikkainen M, Hakkinen AM, et al. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E829-35.
161. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of non-alcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010; 33: 284-6.
162. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-86.
163. Antonopoulos S, Mikros S, Mylonopoulou M, et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233-4.
164. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of non-alcoholic steatohepatitis. Can J Gastroenterol 2003; 17: 713-8.
165. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-4.
166. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46.
167. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with non-alcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004; 174: 193-6.
168. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
169. Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in non-alcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-7.
170. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of non-alcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-4.
171. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46: 1453-63.
172. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-92.
173. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-6.
174. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-71.
175. Athyros VG, Tziomalos K, Daskalopoulos GN, et al. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.
176. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
177. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134-9.
178. Enjoji M, Machida K, Kohjima M, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with non-alcoholic fatty liver disease. Lipids Health Dis 2010; 9: 29.
179. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with non-alcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
180. Abel T, Feher J, Dinya E, et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6-11.
181. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with non-alcoholic steatohepatitis. J Hepatol 1999; 31: 384.
182. Fernandez-Miranda C, Perez-Carreras M, Colina F, et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-5.
183. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with non-alcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-35.
184. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83.
185. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-51.
186. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 194-9.
187. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves non-alcoholic steatohepatitis. J Clin Gastroenterol 2008; 42: 413-8.
188. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
189. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-90.
190. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-90.
191. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
192. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-57.
193. Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003; 112: 1383-94.
194. Yokohama S, Tokusashi Y, Nakamura K, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12: 322-6.
195. Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942-54.
196. Adams LA, Zein CO, Angulo P, et al. A pilot trial of pentoxifylline in non-alcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 2365-8.
197. Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1946-52.
198. Satapathy SK, Sakhuja P, Malhotra V, et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 634-8.
199. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves non-alcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-9.
200. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.
201. Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, et al. Weight reduction and ursodeoxycholic acid in subjects with non-alcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol 2004; 3: 108-12.
202. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of non-alcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.
203. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for non-alcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472-9.
204. Sabuncu T, Nazligul Y, Karaoglanoglu M, et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003; 12: 189-92.
205. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-8.
206. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
207. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-37.
208. Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101: 368-73.
209. de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the non-alcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006; 16: 270-8.
210. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16: 1278-86.
211. Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15: 1154-60.
212. Athyros VG, Tziomalos K, Karagiannis A, et al. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev 2011; 12: 515-24.
213. Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13: 1180-6.
214. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves non-alcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610-7.
215. Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on non-alcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-402.
216. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-40.
217. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of non-alcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106: 71-7.
218. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E vs. vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
219. de Oliveira CP, Stefano JT, de Siqueira ER, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159-65.
220. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-43.
221. Torres D, Jones F, Shaw J, et al. Rosiglitazone vs. rosiglitazone and metformin vs. rosiglitazone and losartan in the treatment of non-alcoholic steatohepatitis (NASH): A 12 month-randomized, prospective, open-label trial. Hepatology 2011; 54: 1631-9.
222. Harrison SA, Fecht W, Brunt EM, et al. Orlistat for overweight subjects with non-alcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-6.
223. Yilmaz Y, Ulukaya E. Toward a biochemical diagnosis of NASH: insights from pathophysiology for distinguishing simple steatosis from steatohepatitis. Curr Med Chem 2011; 18: 725-32.
224. Adams LA, Feldstein AE. Non-invasive diagnosis of non-alcoholic fatty liver and non-alcoholic steatohepatitis. J Dig Dis 2011; 12: 10-6.